Biofrontera Inc. (BFRI) Fair Value 2026

BFRI · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.4 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-28, Biofrontera Inc. (BFRI) trades at $1.59, versus a $7.32 median fair value across its 2 active models — 360.5% above the current price. QOC: 5.4/10. Value Trap Risk: 39/100 (LOW). 2/13 models active.

Key Facts

Ticker
BFRI
Price
$1.59
Quality Score
5.4/10
Value Trap Risk
39/100
Models Active
2/13
Last Updated
Strength: Regime Cross-Sectional suggests +498.7% upside with 46% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is Biofrontera Inc. (BFRI) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Biofrontera Inc. (BFRI) appears undervalued as of : the median of 2 independent fair value estimates is $7.32, 360.5% above the current price of $1.59. Estimates range from $5.12 to $9.52. BFRI scores 5.4/10 on fundamental quality and 39/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. BFRI’s +360.5% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -8.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Biofrontera Inc. Stock in 2026? →

What Fair Value Does Each Model Give BFRI?

2 Intrinsic Value Models vs. Current Price ($1.59)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $9.52 +498.7%
Relative · Low Conviction
 $5.12 +222.2%

All Models Active

All 2 models are displayed above.

What Is Biofrontera Inc. (BFRI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Biofrontera Inc.. Trading at $1.59 against an estimated intrinsic value of $7.32, 2 of 2 active models flag meaningful upside of +360.5% at the median. The most optimistic model, Regime Cross, places fair value at $9.52 (+498.7%), while FTNN — the most conservative — estimates $5.12 (+222.2%). This +276.5% gap reflects genuine analytical uncertainty about Biofrontera Inc.'s intrinsic worth.

What Do the Models Say About BFRI?

2 of 13 models are currently active for BFRI. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for BFRI is $7.32 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does BFRI Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, BFRI ranks #69 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a pharmaceutical industry, Biofrontera Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating BFRI should weigh these sector-specific dynamics alongside our model-derived fair values.

Is BFRI a Value Trap?

CirclFi's Value Trap algorithm assigns BFRI a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Biofrontera Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Biofrontera Inc.'s fundamental quality profile registers 5.4/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +276.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BFRI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BFRI's 2 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Biofrontera Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

TLPHTalphera, Inc.QOC 5.7CVSICV Sciences, Inc.QOC 5.4VRNOVerano Holdings Corp.QOC 5.7YCBDcbdMD, Inc.QOC 5.3RMTIRockwell Medical, Inc.QOC 5.8CGCCanopy Growth CorporationQOC 5.3BUDZWEED, Inc.QOC 4.2HLNHaleon plcQOC 8.5SNOASonoma Pharmaceuticals, Inc.QOC 6.3UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: TLPH · CVSI · VRNO · YCBD · RMTI · CGC · BUDZ · HLN · SNOA · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to BFRI?

7 companies across all industries closest to BFRI’s Quality of Company score of 5.4/10.

AGIGAbundia Global Impact Group IncQOC 5.4VGZVista Gold Corp.QOC 5.4ZTEKZentek Ltd.QOC 5.4DHTIDalrada Technology Group Inc.QOC 5.4RKDAArcadia Biosciences, Inc.QOC 5.4MPUMega Matrix Inc.QOC 5.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AGIG · VGZ · ZTEK · DHTI · RKDA · MPU · NVDA

Where Does BFRI Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

BFRI is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Biofrontera Inc.’s Valuation?

What is Biofrontera Inc.'s intrinsic value in 2026?

CirclFi puts Biofrontera Inc. (BFRI)'s intrinsic value at $7.32 — the median of 2 independent model estimates as of 2026-08-28, ranging from $5.12 to $9.52. The Quality of Company score is 5.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BFRI overvalued or undervalued right now?

At $1.59, 2 of 2 active models suggest BFRI may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $7.32, 360.5% above the current price of $1.59 — a consensus view that BFRI is undervalued. The assessment depends on which methodology best fits Biofrontera Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.4 mean for BFRI?

Biofrontera Inc.'s QOC of 5.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BFRI?

CirclFi analyzes BFRI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is BFRI a value trap in 2026?

Biofrontera Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Biofrontera Inc. (BFRI) has a median fair value of $7.32 — 360.5% above the current price of $1.59 — as of 2026-08-28.” Source: circlfi.com/stock/BFRI/ · Methodology
Primary sources for this BFRI valuation
  • Financial statements: Biofrontera Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001858685) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BFRI as of ; valuations recomputed .